Longeveron Inc.

Longeveron Inc. is a clinical-stage biotechnology company that develops cellular therapies for unmet medical conditions. Its primary investigational product candidate is laromestrocel, an allogeneic cell therapy designed to promote tissue repair and reduce inflammation. The firm focuses on advancing treatments across several therapeutic indications, including hypoplastic left heart syndrome, Alzheimer’s disease, aging-related frailty, and pediatric dilated cardiomyopathy. Its customer and user base includes clinical trial participants, patients, and third-party partners seeking contract development and manufacturing services.

The company is headquartered in Miami, Florida, where it operates a manufacturing facility equipped with eight clean rooms, two research and development laboratories, and warehouse space. Its clinical operations and research activities take place in the United States, and it sponsors a patient registry program located in The Bahamas. Additionally, the organization maintains bone marrow supply agreements with multiple external partners to support product production.

Summary of the business section of Longeveron's latest annual report, written by StockData.

“As of December 31, 2025, we had 37 full-time employees plus 1 employee on leave of absence, zero part-time employees and zero full-time consultants.”